RU2012136148A - Новая кристаллическая форма производного циклопропилбензамида - Google Patents
Новая кристаллическая форма производного циклопропилбензамида Download PDFInfo
- Publication number
- RU2012136148A RU2012136148A RU2012136148/04A RU2012136148A RU2012136148A RU 2012136148 A RU2012136148 A RU 2012136148A RU 2012136148/04 A RU2012136148/04 A RU 2012136148/04A RU 2012136148 A RU2012136148 A RU 2012136148A RU 2012136148 A RU2012136148 A RU 2012136148A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- crystalline form
- xrpd
- cukα
- angstroms
- Prior art date
Links
- NDWNDEKSLWBEML-UHFFFAOYSA-N 2-cyclopropylbenzamide Chemical class NC(=O)C1=CC=CC=C1C1CC1 NDWNDEKSLWBEML-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract 16
- 230000005855 radiation Effects 0.000 claims abstract 13
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 2
- 230000007278 cognition impairment Effects 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010041349 Somnolence Diseases 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000003631 narcolepsy Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Кристаллическая форма соединения (I), 4-{(1S,2S)-2-[(4-клобутилпиперазин-1-ил)карбонил]-циклопропил}-бензамида,2. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (рентгеновской порошковой дифракции) (CuKα) по меньшей мере с одним пиком при примерно 18,3 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.3. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) по меньшей мере с двумя пиками при примерно 4,9 и примерно 18,3 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.4. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) по меньшей мере с тремя пиками при примерно 4,9, примерно 18,3 и примерно 20,4 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.5. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) по меньшей мере с четырьмя пиками при примерно 4,9, примерно 18,3, примерно 19,6 и при 20,4 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.6. Кристаллическая форма соединения (I) по п.3, где картина XRPD (CuKα) дополнительно содержит пики при примерно 16,4 и примерно 16,6, примерно 18,3 и примерно 19,6 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.7. Кристаллическая форма соединения (I) по п.3, где картина XRPD (CuKα) дополнительно содержит пик при примерно 5,3 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.8. Кристаллическая форма соединения (I) по п.1, отлич
Claims (18)
1. Кристаллическая форма соединения (I), 4-{(1S,2S)-2-[(4-клобутилпиперазин-1-ил)карбонил]-циклопропил}-бензамида,
2. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (рентгеновской порошковой дифракции) (CuKα) по меньшей мере с одним пиком при примерно 18,3 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
3. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) по меньшей мере с двумя пиками при примерно 4,9 и примерно 18,3 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
4. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) по меньшей мере с тремя пиками при примерно 4,9, примерно 18,3 и примерно 20,4 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
5. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) по меньшей мере с четырьмя пиками при примерно 4,9, примерно 18,3, примерно 19,6 и при 20,4 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
6. Кристаллическая форма соединения (I) по п.3, где картина XRPD (CuKα) дополнительно содержит пики при примерно 16,4 и примерно 16,6, примерно 18,3 и примерно 19,6 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
7. Кристаллическая форма соединения (I) по п.3, где картина XRPD (CuKα) дополнительно содержит пик при примерно 5,3 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
8. Кристаллическая форма соединения (I) по п.1, отличающаяся тем, что указанная форма имеет картину XRPD (CuKα) с пиками при примерно 4,9, примерно 5,3, примерно 9,0, примерно 12,6, примерно 16,4, примерно 16,6, примерно 18,3, примерно 19,6, примерно 20,4, примерно 21,2, примерно 23,2 и примерно 24,6 °2-тета при измерении с использованием излучения с длиной волны примерно 1,54 ангстрема.
9. Кристаллическая форма соединения (I) по п.1, отличающаяся картиной XRPD по существу такой, как показано на фиг.1.
10. Кристаллическая форма соединения (I) по п.3, отличающаяся термограммой DSC (дифференциальная сканирующая калориметрия), содержащей эндотермический пик примерно при 235°С.
11. Кристаллическая форма соединения (I) по п.10, отличающаяся термограммой DSC, содержащей дополнительный небольшой эндотермический пик при примерно 225°С.
12. Кристаллическая форма соединения (I) по п.3, отличающаяся термограммой DSC по существу такой, как показано на фиг.2.
13. Кристаллическая форма соединения (I) по п.1, которая является по существу чистой.
14. Фармацевтическая композиция, содержащая кристаллическую форму соединения (I) по любому из пп.1-13 вместе с фармацевтически приемлемым вспомогательным средством, разбавителем и/или носителем.
15. Кристаллическая форма соединения (I) по любому из пп.1-13 для применения в терапии.
16. Кристаллическая форма соединения (I) по любому из пп.1-13 для применения в изготовлении лекарственного средства для лечения расстройства, выбранного из шизофрении, нарколепсии, чрезмерной дневной сонливости, ожирения, синдрома дефицита внимания и гиперактивности, боли, невропатической боли, болезни Альцгеймера, когнитивного дефицита и когнитивного дефицита, ассоциированного с шизофренией.
17. Кристаллическая форма соединения (I) по любому из пп.1-13 для применения в лечении шизофрении, нарколепсии, чрезмерной дневной сонливости, ожирения, синдрома дефицита внимания и гиперактивности, боли, невропатической боли, болезни Альцгеймера, когнитивного дефицита и когнитивного дефицита, ассоциированного с шизофренией.
18. Способ лечения расстройства, выбранного из шизофрении, нарколепсии, чрезмерной дневной сонливости, ожирения, синдрома дефицита внимания и гиперактивности, боли, невропатической боли, болезни Альцгеймера, когнитивного дефицита и когнитивного дефицита, ассоциированного с шизофренией, у теплокровного животного, включающий введение указанному животному, нуждающемуся в таком лечении, терапевтически эффективного количества кристаллической формы соединения (I) по любому из пп.1-13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30558310P | 2010-02-18 | 2010-02-18 | |
| US61/305,583 | 2010-02-18 | ||
| PCT/SE2011/050172 WO2011102795A1 (en) | 2010-02-18 | 2011-02-17 | New crystalline form of a cyclopropyl benzamide derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012136148A true RU2012136148A (ru) | 2014-03-27 |
Family
ID=44370080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012136148/04A RU2012136148A (ru) | 2010-02-18 | 2011-02-17 | Новая кристаллическая форма производного циклопропилбензамида |
| RU2012139082/04A RU2012139082A (ru) | 2010-02-18 | 2011-02-17 | Способы получения производных циклопропиламида и связанных с ними промежуточных соединений |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012139082/04A RU2012139082A (ru) | 2010-02-18 | 2011-02-17 | Способы получения производных циклопропиламида и связанных с ними промежуточных соединений |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20110201623A1 (ru) |
| EP (2) | EP2536702A4 (ru) |
| JP (3) | JP2013520413A (ru) |
| KR (2) | KR20130004296A (ru) |
| CN (2) | CN103168027B (ru) |
| AR (2) | AR080204A1 (ru) |
| AU (2) | AU2011218491C1 (ru) |
| BR (2) | BR112012020629A2 (ru) |
| CA (2) | CA2790040A1 (ru) |
| CL (2) | CL2012002259A1 (ru) |
| CO (1) | CO6592109A2 (ru) |
| ES (1) | ES2541857T3 (ru) |
| IL (1) | IL221431A (ru) |
| MX (2) | MX336333B (ru) |
| NZ (2) | NZ601920A (ru) |
| RU (2) | RU2012136148A (ru) |
| SG (3) | SG10201501226VA (ru) |
| TW (2) | TWI494301B (ru) |
| WO (2) | WO2011102795A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140047T1 (en) | 2007-08-22 | 2014-02-14 | Astrazeneca Ab | Cycloptopyl amide derivatives |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US20110201622A1 (en) * | 2010-02-18 | 2011-08-18 | Collins Craig D | Solid Forms Comprising A Cyclopropyl Amide Derivative |
| BR112012020629A2 (pt) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
| CN111718281A (zh) * | 2013-03-22 | 2020-09-29 | 默克专利有限公司 | 用于制备有机电致发光器件用材料的合成结构单元 |
| FR3003466B1 (fr) * | 2013-03-22 | 2015-08-07 | Servier Lab | Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques |
| CN103342655A (zh) * | 2013-07-02 | 2013-10-09 | 扬州大学 | 取代乙二酮双苯胺希夫碱合成取代酰胺的新方法 |
| JP2026000886A (ja) | 2024-06-18 | 2026-01-06 | イーライ リリー アンド カンパニー | Ｇｉｐ受容体アゴニスト化合物 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (ru) | 1963-04-04 | 1900-01-01 | ||
| NL128365C (ru) | 1963-11-05 | |||
| US3449427A (en) * | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
| US3697506A (en) * | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
| US3686335A (en) * | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| CS244821B2 (en) | 1983-06-16 | 1986-08-14 | Boehringer Ingelheim Ltd | Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas |
| DE3418167A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden |
| DE3600288A1 (de) | 1986-01-08 | 1987-07-16 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten |
| DE3618004A1 (de) | 1986-05-28 | 1987-12-03 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| CA2033390A1 (en) * | 1989-12-29 | 1991-06-30 | Susumu Nakagawa | 2-(2-cyclopropylpyrrolidin-4-ylthio) carbapenem derivatives |
| BR9206396A (pt) | 1991-08-22 | 1994-12-13 | Monsanto Co | Pirazolilsulfoniluréias herbicidas de proteção |
| DE4131139A1 (de) * | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
| KR100296810B1 (ko) * | 1993-03-12 | 2001-10-24 | 로렌스 티. 마이젠헬더 | 결정성세프티오퍼유리산 |
| BR9509760A (pt) | 1994-11-23 | 1998-06-30 | Neurogen Corp | Composto |
| US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
| EP0968200A1 (en) | 1997-02-24 | 2000-01-05 | ZymoGenetics, Inc. | Calcitonin mimetics |
| US6160134A (en) | 1997-12-24 | 2000-12-12 | Bristol-Myers Squibb Co. | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines |
| WO1999037304A1 (en) | 1998-01-27 | 1999-07-29 | Aventis Pharmaceuticals Products Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| US6383520B1 (en) * | 1998-06-26 | 2002-05-07 | Chugai Seiyaku Kabushiki Kaisha | Fine powder of L-α-aminoadipic acid derivative, oral solid preparations containing the same, and method for treatment of bulk powders |
| WO2000040572A1 (en) | 1999-01-08 | 2000-07-13 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
| US6284761B1 (en) * | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6936602B1 (en) | 1999-06-16 | 2005-08-30 | Takeda Chemical Industries, Ltd. | Benzazepine derivatives, process for the preparation of the same and uses thereof |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| AU6872401A (en) | 2000-06-29 | 2002-01-14 | Abbott Lab | Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| AU8066701A (en) | 2000-07-20 | 2002-02-05 | Neurogen Corp | Capsaicin receptor ligands |
| US6888012B2 (en) | 2000-12-25 | 2005-05-03 | Ajinomoto Co., Inc. | Process for producing optically active halohydrin compound |
| EA005974B1 (ru) * | 2001-02-23 | 2005-08-25 | Мерк Энд Ко., Инк. | N-замещенные неарильные гетероциклические антагонисты nmda/nr2b |
| JP2005502623A (ja) | 2001-07-02 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 置換ピペラジンおよびジアゼパン |
| WO2003014110A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Benzazepine derivative, process for producing the same, and use |
| EP1442038A4 (en) | 2001-09-26 | 2005-01-05 | Merck & Co Inc | CRYSTALLINE FORMS OF CARBAPENEM ANTIBIOTICS AND MANUFACTURING METHOD |
| US20050143372A1 (en) * | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| BR0308525A (pt) * | 2002-03-22 | 2005-02-01 | Lg Life Sciences Ltd | Formas cristalinas |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| US20040077618A1 (en) | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| ATE384724T1 (de) | 2002-12-13 | 2008-02-15 | Smithkline Beecham Corp | Cyclopropylverbindungen als ccr5 antagonisten |
| DE602004015269D1 (de) * | 2003-04-23 | 2008-09-04 | Glaxo Group Ltd | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. |
| AU2004236240C1 (en) | 2003-05-01 | 2010-11-04 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole compounds useful as kinase inhibitors |
| AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| DE602004026629D1 (de) | 2003-12-15 | 2010-05-27 | Japan Tobacco Inc | Cyclopropanderivate und ihre pharmazeutische verwendung |
| BRPI0418939A (pt) | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
| TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| NZ554722A (en) | 2004-09-29 | 2010-07-30 | Mitsubishi Tanabe Pharma Corp | 6-(Pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| SI1802307T1 (sl) | 2004-10-15 | 2008-08-31 | Glaxo Group Ltd | Derivati pirolidina kot ligandi histaminskih receptorjev |
| MX2007007220A (es) | 2004-12-27 | 2007-08-20 | Astrazeneca Ab | Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos. |
| EP1844052A1 (en) * | 2005-01-26 | 2007-10-17 | Pharmacia & Upjohn Company LLC | Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
| TW200640863A (en) * | 2005-02-15 | 2006-12-01 | Glaxo Group Ltd | Compounds which potentiate glutamate receptor and uses thereof in medicine |
| EP2607362B1 (en) | 2005-02-17 | 2014-12-31 | Astellas Pharma Inc. | Piperidine and piperazine carboxylates as FAAH inhibitors |
| JP2008534488A (ja) | 2005-03-25 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害剤としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物 |
| EP1896483A2 (en) | 2005-03-28 | 2008-03-12 | Pharmacia & Upjohn Company LLC | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| CA2602227A1 (en) | 2005-03-28 | 2006-10-05 | Michael Dalton Ennis | 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| JP2008534573A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害剤としての４−ピペラジノチエノ［２，３−ｄ］ピリミジン化合物 |
| MX2008000745A (es) | 2005-07-15 | 2008-03-14 | Schering Corp | Derivados de quinazolina utiles en el tratamiento del cancer. |
| TW200740779A (en) * | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| UA96424C2 (ru) * | 2005-09-16 | 2011-11-10 | Янссен Фармацевтика Н.В. | Циклопропил амины как модуляторы н3 рецепторов гистамина |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| PT1951699E (pt) | 2005-10-31 | 2012-12-26 | Janssen Pharmaceutica Nv | Processos para a preparação de derivados de ciclopropilamida |
| CN101365686A (zh) | 2005-12-21 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的杂环衍生物 |
| WO2007076140A2 (en) | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| BRPI0707916A2 (pt) * | 2006-01-13 | 2011-05-17 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos |
| CN101384581B (zh) | 2006-02-17 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物 |
| JP2009528240A (ja) | 2006-03-01 | 2009-08-06 | セメンテク・ピーティーワイ・リミテッド | メーソンリー部材用マトリックス及びその製造方法 |
| JP2009132621A (ja) | 2006-03-13 | 2009-06-18 | Ajinomoto Co Inc | シクロプロピルアミド化合物の製造方法 |
| AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| WO2007138928A1 (ja) | 2006-05-26 | 2007-12-06 | Kaneka Corporation | 光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法 |
| MX2008016343A (es) | 2006-06-23 | 2009-01-19 | Abbott Lab | Derivados ciclopropil amina como moduladores del receptro de histamina h3. |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| WO2008003702A2 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine h4 receptor |
| GB0615620D0 (en) * | 2006-08-05 | 2006-09-13 | Astrazeneca Ab | A process for the preparation of optically active intermediates |
| EP2056828A4 (en) | 2006-08-21 | 2010-06-23 | Merck Sharp & Dohme | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS |
| TW200828371A (en) * | 2006-09-21 | 2008-07-01 | Matsushita Electric Industrial Co Ltd | Chip-type filter |
| DE102006056526A1 (de) | 2006-11-30 | 2008-06-05 | Archimica Gmbh | Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
| DE602008002598D1 (en) | 2007-06-11 | 2010-10-28 | Hoffmann La Roche | Cyclohexylderivate |
| HRP20140047T1 (en) * | 2007-08-22 | 2014-02-14 | Astrazeneca Ab | Cycloptopyl amide derivatives |
| CN101815512B (zh) * | 2007-10-04 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | 环丙基芳基酰胺衍生物和其用途 |
| CL2009000004A1 (es) | 2008-01-15 | 2010-02-19 | Lilly Co Eli | Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia. |
| DE102008049371A1 (de) | 2008-03-06 | 2009-09-10 | Mühlbauer Ag | Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür |
| KR20110005248A (ko) * | 2008-03-20 | 2011-01-17 | 포레스트 래보러토리즈 홀딩스 리미티드 | 스테아로일-ｃｏａ 탈포화효소의 억제제로서의 신규한 피페라진 유도체 |
| EP2300422B1 (en) * | 2008-05-08 | 2014-11-05 | Evotec AG | Azetidines as histamine h3 receptor antagonists |
| US8586607B2 (en) | 2008-07-28 | 2013-11-19 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
| CN101462980B (zh) | 2009-01-05 | 2013-01-09 | 扬州天辰精细化工有限公司 | 2，6—二氟苯甲酰胺的工业化生产方法 |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US20110201622A1 (en) | 2010-02-18 | 2011-08-18 | Collins Craig D | Solid Forms Comprising A Cyclopropyl Amide Derivative |
| BR112012020629A2 (pt) * | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
-
2011
- 2011-02-17 BR BR112012020629A patent/BR112012020629A2/pt not_active IP Right Cessation
- 2011-02-17 EP EP11744975.1A patent/EP2536702A4/en not_active Withdrawn
- 2011-02-17 AR ARP110100485 patent/AR080204A1/es unknown
- 2011-02-17 MX MX2012009480A patent/MX336333B/es unknown
- 2011-02-17 KR KR20127024174A patent/KR20130004296A/ko not_active Withdrawn
- 2011-02-17 US US13/029,362 patent/US20110201623A1/en not_active Abandoned
- 2011-02-17 RU RU2012136148/04A patent/RU2012136148A/ru not_active Application Discontinuation
- 2011-02-17 EP EP20110744974 patent/EP2536685B1/en not_active Not-in-force
- 2011-02-17 SG SG10201501226VA patent/SG10201501226VA/en unknown
- 2011-02-17 NZ NZ60192011A patent/NZ601920A/en not_active IP Right Cessation
- 2011-02-17 RU RU2012139082/04A patent/RU2012139082A/ru not_active Application Discontinuation
- 2011-02-17 US US13/579,605 patent/US9012452B2/en not_active Expired - Fee Related
- 2011-02-17 SG SG2012059473A patent/SG183274A1/en unknown
- 2011-02-17 WO PCT/SE2011/050172 patent/WO2011102795A1/en not_active Ceased
- 2011-02-17 SG SG2012055240A patent/SG182732A1/en unknown
- 2011-02-17 CN CN201180019632.7A patent/CN103168027B/zh not_active Expired - Fee Related
- 2011-02-17 JP JP2012553849A patent/JP2013520413A/ja not_active Ceased
- 2011-02-17 AU AU2011218491A patent/AU2011218491C1/en not_active Ceased
- 2011-02-17 TW TW100105300A patent/TWI494301B/zh not_active IP Right Cessation
- 2011-02-17 CA CA 2790040 patent/CA2790040A1/en not_active Abandoned
- 2011-02-17 NZ NZ60211011A patent/NZ602110A/en not_active IP Right Cessation
- 2011-02-17 CA CA 2788444 patent/CA2788444A1/en not_active Abandoned
- 2011-02-17 ES ES11744974.4T patent/ES2541857T3/es active Active
- 2011-02-17 JP JP2012553850A patent/JP2013520414A/ja active Pending
- 2011-02-17 AU AU2011218492A patent/AU2011218492B2/en not_active Ceased
- 2011-02-17 BR BR112012020782A patent/BR112012020782A2/pt not_active IP Right Cessation
- 2011-02-17 CN CN2011800196365A patent/CN102869651A/zh active Pending
- 2011-02-17 AR ARP110100486 patent/AR080205A1/es unknown
- 2011-02-17 KR KR20127021548A patent/KR20130002316A/ko not_active Withdrawn
- 2011-02-17 WO PCT/SE2011/050171 patent/WO2011102794A1/en not_active Ceased
- 2011-02-17 TW TW100105296A patent/TWI520945B/zh not_active IP Right Cessation
- 2011-02-17 MX MX2012009473A patent/MX2012009473A/es active IP Right Grant
-
2012
- 2012-08-13 IL IL221431A patent/IL221431A/en not_active IP Right Cessation
- 2012-08-16 CL CL2012002259A patent/CL2012002259A1/es unknown
- 2012-08-17 CL CL2012002286A patent/CL2012002286A1/es unknown
- 2012-08-17 CO CO12140266A patent/CO6592109A2/es unknown
-
2015
- 2015-08-14 JP JP2015160029A patent/JP2016006103A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида | |
| JP2021530565A5 (ru) | ||
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JP2022186995A5 (ru) | ||
| RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
| JP2016128501A5 (ru) | ||
| UA129695C2 (uk) | Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2 | |
| JP2017535550A5 (ru) | ||
| RU2009124541A (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| RU2014145544A (ru) | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека | |
| NZ594741A (en) | Specific diarylhydantoin and diarylthiohydantoin compounds | |
| JP2018531280A5 (ru) | ||
| RU2011151611A (ru) | Композиции для модуляции киназного каскада и способы их применения | |
| RU2010133483A (ru) | Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты | |
| JP2016510768A5 (ru) | ||
| JP2015522037A5 (ru) | ||
| AR073226A1 (es) | Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida | |
| JP2013523623A5 (ru) | ||
| RU2017134709A (ru) | П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения | |
| MX2014010910A (es) | Sales novedosas de trimebutina basadas en sulfonato. | |
| RU2012136921A (ru) | Твердые формы, содержащие производные циклопропиламида | |
| RU2015114085A (ru) | Кристаллические формы производных дигидропиримидина | |
| JP2018516946A5 (ru) | ||
| JP2020517676A5 (ru) | ||
| JPWO2021026180A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20170126 |